Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

European Commission Approves Bristol-Myers Squibb Co' s Daklinza (daclatasvir) across multiple genotypes for treatment of Chronic Hepatitis C Infection


Wednesday, 27 Aug 2014 05:00am EDT 

Bristol-Myers Squibb Co:Announced that European Commission has approved Daklinza (daclatasvir), potent, pan-genotypic NS5A replication complex inhibitor ( in vitro ).Daklinza use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for treatment of chronic hepatitis C virus (HCV) infection in adults.Daklinza, when used in combination with sofosbuvir, is an all-oral, interferon-free regimen that provided cure rates of up to 100 pct in clinical trials, including patients with advanced liver disease, genotype 3 and those who have previously failed treatment with protease inhibitors.Daklinza is first NS5A complex inhibitor approved in European Union (EU) and will be available for use in combination with other medicinal products, providing a shorter treatment duration (12 or 24 weeks) compared to 48 weeks of treatment with interferon- and ribavirin-based regimens. 

Company Quote

59.19
1.5 +2.60%
17 Dec 2014